tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2023 May 23;10(7)
fad275.
doi: 10.1093/ofid/ofad275. eCollection 2023 Jul. Association Between SARS-CoV-2 Variants and Frequency of Acute Symptoms: Analysis of a Multi-institutional Prospective Cohort Study-December 20, 2020-June 20, 2022
Ralph C Wang[SUP] 1 [/SUP], Michael Gottlieb[SUP] 2 [/SUP], Juan Carlos C Montoy[SUP] 1 [/SUP], Robert M Rodriguez[SUP] 1 [/SUP], Huihui Yu[SUP] 3 [/SUP], Erica S Spatz[SUP] 3 [/SUP], Christopher W Chandler[SUP] 4 [/SUP], Joann G Elmore[SUP] 4 5 [/SUP], Paavali A Hannikainen[SUP] 6 [/SUP], Anna Marie Chang[SUP] 6 [/SUP], Mandy Hill[SUP] 7 [/SUP], Ryan M Huebinger[SUP] 7 [/SUP], Ahamed H Idris[SUP] 8 [/SUP], Katherine Koo[SUP] 9 [/SUP], Shu-Xia Li[SUP] 3 [/SUP], Samuel McDonald[SUP] 8 [/SUP], Graham Nichol[SUP] 10 [/SUP], Kelli N O'Laughlin[SUP] 11 [/SUP], Ian D Plumb[SUP] 12 [/SUP], Michelle Santangelo[SUP] 13 [/SUP], Sharon Saydah[SUP] 12 [/SUP], Kari A Stephens[SUP] 14 [/SUP], Arjun K Venkatesh[SUP] 3 15 [/SUP], Robert A Weinstein[SUP] 9 [/SUP]; Innovative Support for Patients with SARS-CoV-2 Infections Registry (INSPIRE) Group
Collaborators, Affiliations
Background: While prior work examining severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern focused on hospitalization and death, less is known about differences in clinical presentation. We compared the prevalence of acute symptoms across pre-Delta, Delta, and Omicron.
Methods: We conducted an analysis of the Innovative Support for Patients with SARS-CoV-2 Infections Registry (INSPIRE), a cohort study enrolling symptomatic SARS-CoV-2-positive participants. We determined the association between the pre-Delta, Delta, and Omicron time periods and the prevalence of 21 coronavirus disease 2019 (COVID-19) acute symptoms.
Results: We enrolled 4113 participants from December 2020 to June 2022. Pre-Delta vs Delta vs Omicron participants had increasing sore throat (40.9%, 54.6%, 70.6%; P < .001), cough (50.9%, 63.3%, 66.7%; P < .001), and runny noses (48.9%, 71.3%, 72.9%; P < .001). We observed reductions during Omicron in chest pain (31.1%, 24.2%, 20.9%; P < .001), shortness of breath (42.7%, 29.5%, 27.5%; P < .001), loss of taste (47.1%, 61.8%, 19.2%; P < .001), and loss of smell (47.5%, 55.6%, 20.0%; P < .001). After adjustment, those infected during Omicron had significantly higher odds of sore throat vs pre-Delta (odds ratio [OR], 2.76; 95% CI, 2.26-3.35) and Delta (OR, 1.96; 95% CI, 1.69-2.28).
Conclusions: Participants infected during Omicron were more likely to report symptoms of common respiratory viruses, such as sore throat, and less likely to report loss of smell and taste.
Trial registration: NCT04610515.
Keywords: COVID-19; COVID-19 symptoms; SARS-COV-2; variants of concern.
. 2023 May 23;10(7)
fad275.doi: 10.1093/ofid/ofad275. eCollection 2023 Jul. Association Between SARS-CoV-2 Variants and Frequency of Acute Symptoms: Analysis of a Multi-institutional Prospective Cohort Study-December 20, 2020-June 20, 2022
Ralph C Wang[SUP] 1 [/SUP], Michael Gottlieb[SUP] 2 [/SUP], Juan Carlos C Montoy[SUP] 1 [/SUP], Robert M Rodriguez[SUP] 1 [/SUP], Huihui Yu[SUP] 3 [/SUP], Erica S Spatz[SUP] 3 [/SUP], Christopher W Chandler[SUP] 4 [/SUP], Joann G Elmore[SUP] 4 5 [/SUP], Paavali A Hannikainen[SUP] 6 [/SUP], Anna Marie Chang[SUP] 6 [/SUP], Mandy Hill[SUP] 7 [/SUP], Ryan M Huebinger[SUP] 7 [/SUP], Ahamed H Idris[SUP] 8 [/SUP], Katherine Koo[SUP] 9 [/SUP], Shu-Xia Li[SUP] 3 [/SUP], Samuel McDonald[SUP] 8 [/SUP], Graham Nichol[SUP] 10 [/SUP], Kelli N O'Laughlin[SUP] 11 [/SUP], Ian D Plumb[SUP] 12 [/SUP], Michelle Santangelo[SUP] 13 [/SUP], Sharon Saydah[SUP] 12 [/SUP], Kari A Stephens[SUP] 14 [/SUP], Arjun K Venkatesh[SUP] 3 15 [/SUP], Robert A Weinstein[SUP] 9 [/SUP]; Innovative Support for Patients with SARS-CoV-2 Infections Registry (INSPIRE) Group
Collaborators, Affiliations
- PMID: 37426947
- PMCID: PMC10327880
- DOI: 10.1093/ofid/ofad275
Background: While prior work examining severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern focused on hospitalization and death, less is known about differences in clinical presentation. We compared the prevalence of acute symptoms across pre-Delta, Delta, and Omicron.
Methods: We conducted an analysis of the Innovative Support for Patients with SARS-CoV-2 Infections Registry (INSPIRE), a cohort study enrolling symptomatic SARS-CoV-2-positive participants. We determined the association between the pre-Delta, Delta, and Omicron time periods and the prevalence of 21 coronavirus disease 2019 (COVID-19) acute symptoms.
Results: We enrolled 4113 participants from December 2020 to June 2022. Pre-Delta vs Delta vs Omicron participants had increasing sore throat (40.9%, 54.6%, 70.6%; P < .001), cough (50.9%, 63.3%, 66.7%; P < .001), and runny noses (48.9%, 71.3%, 72.9%; P < .001). We observed reductions during Omicron in chest pain (31.1%, 24.2%, 20.9%; P < .001), shortness of breath (42.7%, 29.5%, 27.5%; P < .001), loss of taste (47.1%, 61.8%, 19.2%; P < .001), and loss of smell (47.5%, 55.6%, 20.0%; P < .001). After adjustment, those infected during Omicron had significantly higher odds of sore throat vs pre-Delta (odds ratio [OR], 2.76; 95% CI, 2.26-3.35) and Delta (OR, 1.96; 95% CI, 1.69-2.28).
Conclusions: Participants infected during Omicron were more likely to report symptoms of common respiratory viruses, such as sore throat, and less likely to report loss of smell and taste.
Trial registration: NCT04610515.
Keywords: COVID-19; COVID-19 symptoms; SARS-COV-2; variants of concern.